Arvinas (ARVN) Q2 2026 Earnings Call Transcript
Arvinas (ARVN) reported Q2 2026 revenue of $249.7 million, including $62.5 million from a Rigel license and a $50 million Pfizer (PFE) milestone tied to FDA approval of VEPPANU. Net income was $169.4 million and diluted EPS $2.58. Cash and marketable securities were $567.9 million, funding into 2H 2028. The call also discussed clinical timing updates and an FDA-requested delay for ARV-102.
How this was made
The 30-second read
Why it matters
Traders can update expectations for (1) cash runway and near-term revenue durability from licensing/milestones, and (2) the probability-weighted timing of upcoming clinical data catalysts given disclosed regulatory delay and enrollment issues.
Market read
The call provides a concrete earnings print with licensing-driven revenue and a specific FDA milestone, plus new risk framing around regulatory delay and clinical enrollment/timeline adjustments.
What to watch
ARV-102 is described as effectively under a US clinical hold after IND submission, and ARV-393 enrollment was challenged at subtherapeutic dosing, both of which can pressure future catalyst timing despite strong reported quarter results.
Background
This is a transcript of Arvinas’ Q2 2026 earnings call, covering financial results, licensing milestones, and updated clinical/program timelines.
Ticker impact
Arvinas reported Q2 2026 revenue of $249.7M, including a $50M Pfizer VEPPANU milestone tied to the first-ever FDA approval of a PROTAC degrader.
Near-term bias positive on the FDA-approval and Pfizer milestone cash, partially offset by disclosed clinical hold and revised timelines.
The article contains concrete financial results and a specific regulatory milestone (VEPPANU FDA approval) plus new operational risk disclosures (FDA asked to wait after IND; enrollment delays at subtherapeutic dosing).
Market effects
Reinforces investor appetite for PROTAC platform monetization via licensing and milestones, while underscoring that FDA interactions can create clinical-hold style delays.
Limited direct regional read-through; primarily US FDA-driven regulatory and commercialization signal.
Mentions finalizing a global registrational path using feedback from major agencies, which can influence expectations for international development timelines.
Counterpoint
The headline milestone cash may not translate into near-term operating leverage if deferred revenue recognition and collaboration liabilities mask ongoing development burn and future obligations.
Key entities
- companyArvinas
Reported Q2 2026 results and discussed FDA approval of VEPPANU, Pfizer milestone revenue, and updated timelines for multiple PROTAC programs.
- partnerPfizer
Collaboration counterparty whose VEPPANU-related milestone payment of $50M was triggered by first-ever FDA approval of a PROTAC degrader.
- regulatorFDA
Requested Arvinas to wait after IND submission for ARV-102, described as a clinical hold before starting US studies.
